322 related articles for article (PubMed ID: 24503888)
1. Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia.
Sun P; Solé M; Unzeta M
Cerebrovasc Dis; 2014; 37(3):171-80. PubMed ID: 24503888
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of the multitarget compound DPH-4 on human SSAO/VAP-1-expressing hCMEC/D3 cells under oxygen-glucose deprivation conditions: an in vitro experimental model of cerebral ischaemia.
Sun P; Esteban G; Inokuchi T; Marco-Contelles J; Weksler BB; Romero IA; Couraud PO; Unzeta M; Solé M
Br J Pharmacol; 2015 Nov; 172(22):5390-402. PubMed ID: 26362823
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control.
Sun P; Hernandez-Guillamón M; Campos-Martorell M; Simats A; Montaner J; Unzeta M; Solé M
Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):542-553. PubMed ID: 29175057
[TBL] [Abstract][Full Text] [Related]
4. Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases.
Solé M; Unzeta M
Biol Cell; 2011 Nov; 103(11):543-57. PubMed ID: 21819380
[TBL] [Abstract][Full Text] [Related]
5. Cross-talk between Aβ and endothelial SSAO/VAP-1 accelerates vascular damage and Aβ aggregation related to CAA-AD.
Solé M; Miñano-Molina AJ; Unzeta M
Neurobiol Aging; 2015 Feb; 36(2):762-75. PubMed ID: 25457560
[TBL] [Abstract][Full Text] [Related]
6. VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke.
Hernandez-Guillamon M; Solé M; Delgado P; García-Bonilla L; Giralt D; Boada C; Penalba A; García S; Flores A; Ribó M; Alvarez-Sabin J; Ortega-Aznar A; Unzeta M; Montaner J
Cerebrovasc Dis; 2012; 33(1):55-63. PubMed ID: 22133888
[TBL] [Abstract][Full Text] [Related]
7. Soluble Vascular Adhesion Protein-1 Mediates Spermine Oxidation as Semicarbazide-Sensitive Amine Oxidase: Possible Role in Proliferative Diabetic Retinopathy.
Murata M; Noda K; Kawasaki A; Yoshida S; Dong Y; Saito M; Dong Z; Ando R; Mori S; Saito W; Kanda A; Ishida S
Curr Eye Res; 2017 Dec; 42(12):1674-1683. PubMed ID: 28937866
[TBL] [Abstract][Full Text] [Related]
8. A peptide inhibitor of vascular adhesion protein-1 (VAP-1) blocks leukocyte-endothelium interactions under shear stress.
Yegutkin GG; Salminen T; Koskinen K; Kurtis C; McPherson MJ; Jalkanen S; Salmi M
Eur J Immunol; 2004 Aug; 34(8):2276-85. PubMed ID: 15259025
[TBL] [Abstract][Full Text] [Related]
9. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications.
Stolen CM; Madanat R; Marti L; Kari S; Yegutkin GG; Sariola H; Zorzano A; Jalkanen S
FASEB J; 2004 Apr; 18(6):702-4. PubMed ID: 14977883
[TBL] [Abstract][Full Text] [Related]
10. Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke.
Hernandez-Guillamon M; Garcia-Bonilla L; Solé M; Sosti V; Parés M; Campos M; Ortega-Aznar A; Domínguez C; Rubiera M; Ribó M; Quintana M; Molina CA; Alvarez-Sabín J; Rosell A; Unzeta M; Montaner J
Stroke; 2010 Jul; 41(7):1528-35. PubMed ID: 20538694
[TBL] [Abstract][Full Text] [Related]
11. Vascular adhesion protein-1 in human ischaemic stroke.
Airas L; Lindsberg PJ; Karjalainen-Lindsberg ML; Mononen I; Kotisaari K; Smith DJ; Jalkanen S
Neuropathol Appl Neurobiol; 2008 Aug; 34(4):394-402. PubMed ID: 18005095
[TBL] [Abstract][Full Text] [Related]
12. Origins of serum semicarbazide-sensitive amine oxidase.
Stolen CM; Yegutkin GG; Kurkijärvi R; Bono P; Alitalo K; Jalkanen S
Circ Res; 2004 Jul; 95(1):50-7. PubMed ID: 15178639
[TBL] [Abstract][Full Text] [Related]
13. Physiological and pathological implications of semicarbazide-sensitive amine oxidase.
Yu PH; Wright S; Fan EH; Lun ZR; Gubisne-Harberle D
Biochim Biophys Acta; 2003 Apr; 1647(1-2):193-9. PubMed ID: 12686132
[TBL] [Abstract][Full Text] [Related]
14. Blood-brain barrier dysfunction underlying Alzheimer's disease is induced by an SSAO/VAP-1-dependent cerebrovascular activation with enhanced Aβ deposition.
Solé M; Esteban-Lopez M; Taltavull B; Fábregas C; Fadó R; Casals N; Rodríguez-Álvarez J; Miñano-Molina AJ; Unzeta M
Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2189-2202. PubMed ID: 31047972
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of semicarbazide-sensitive amine oxidase reduces atherosclerosis in apolipoprotein E-deficient mice.
Wang SH; Yu TY; Tsai FC; Weston CJ; Lin MS; Hung CS; Kao HL; Li YI; Solé M; Unzeta M; Chen YL; Chuang LM; Li HY
Transl Res; 2018 Jul; 197():12-31. PubMed ID: 29653075
[TBL] [Abstract][Full Text] [Related]
16. Vascular adhesion protein-1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia.
Xu HL; Salter-Cid L; Linnik MD; Wang EY; Paisansathan C; Pelligrino DA
J Pharmacol Exp Ther; 2006 Apr; 317(1):19-29. PubMed ID: 16339390
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase.
Salter-Cid LM; Wang E; O'Rourke AM; Miller A; Gao H; Huang L; Garcia A; Linnik MD
J Pharmacol Exp Ther; 2005 Nov; 315(2):553-62. PubMed ID: 16081681
[TBL] [Abstract][Full Text] [Related]
18. Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner.
Abella A; García-Vicente S; Viguerie N; Ros-Baró A; Camps M; Palacín M; Zorzano A; Marti L
Diabetologia; 2004 Mar; 47(3):429-438. PubMed ID: 14968297
[TBL] [Abstract][Full Text] [Related]
19. SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease.
Unzeta M; Hernàndez-Guillamon M; Sun P; Solé M
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805974
[TBL] [Abstract][Full Text] [Related]
20. Obesity of mice lacking VAP-1/SSAO by Aoc3 gene deletion is reproduced in mice expressing a mutated vascular adhesion protein-1 (VAP-1) devoid of amine oxidase activity.
Jargaud V; Bour S; Tercé F; Collet X; Valet P; Bouloumié A; Guillemot JC; Mauriège P; Jalkanen S; Stolen C; Salmi M; Smith DJ; Carpéné C
J Physiol Biochem; 2021 Feb; 77(1):141-154. PubMed ID: 32712883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
